Written question asked by Baroness Masham of Ilton (Crossbench) on Monday, 23 March 2015, in the House of Lords. It was due for an answer on Monday, 30 March 2015. It was answered by Earl Howe (Conservative) on Wednesday, 25 March 2015 on behalf of the Department of Health.
Orphan Drugs
- Question
-
To ask Her Majesty’s Government what steps they are taking to ensure that any decision around ultra-orphan drugs will be referred to the National Institute for Health and Care Excellence Highly Specialised Technologies Evaluation Committee.
- Answer
-
We have referred a number of high cost, low volume technologies to the National Institute for Health and Care Excellence (NICE) for evaluation under its highly specialised technologies work programme. We will continue to do so for technologies that meet the specified criteria and where a NICE evaluation would add value. Further information about the process by which topics are selected for referral to NICE’s highly specialised technologies work programme is available at:
www.nice.org.uk/about/what-we-do/our-programmes/topic-selection
Secondary information
- Type
- Written question
- Reference
- HL5942
- Session
- 2014-15
- Subjects
- National Institute for Health and Care Excellence Orphan drugs
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2015-03-25 13:32:52 +0000
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/lords/2014-15/HL5942
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/lords/2014-15/HL5942
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/lords/2014-15/HL5942